{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:33:10Z","timestamp":1779244390659,"version":"3.51.4"},"reference-count":112,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":2969,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.rmed.2004.11.006","type":"journal-article","created":{"date-parts":[[2005,1,11]],"date-time":"2005-01-11T07:29:51Z","timestamp":1105428591000},"page":"670-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":136,"title":["COPD, a multicomponent disease: implications for management"],"prefix":"10.1016","volume":"99","author":[{"given":"A.G.N.","family":"Agusti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2004.11.006_bib1","series-title":"The global burden of disease","first-page":"361","article-title":"Alternative visions of the future","author":"Murray","year":"1996"},{"key":"10.1016\/j.rmed.2004.11.006_bib2","first-page":"12564","article-title":"Global initiative for chronic obstructive lung disease","volume":"163","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"10.1016\/j.rmed.2004.11.006_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000195745","article-title":"Host\u2013microbe relationships in chronic respiratory infection","volume":"55","author":"Cole","year":"1989","journal-title":"Respiration"},{"issue":"4","key":"10.1016\/j.rmed.2004.11.006_bib4","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1164\/ajrccm\/146.4.1067","article-title":"Bacterial infection in chronic obstructive pulmonary disease","volume":"146","author":"Murphy","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmed.2004.11.006_bib5","first-page":"388","article-title":"The pathophysiological consequences of smoking on the respiratory system","volume":"72","author":"Jones","year":"1981","journal-title":"Canadian Journal of Public Health"},{"issue":"5 Suppl 1","key":"10.1016\/j.rmed.2004.11.006_bib6","doi-asserted-by":"crossref","first-page":"286S","DOI":"10.1378\/chest.117.5_suppl_1.286S","article-title":"Bacterial infection and the pathogenesis of COPD","volume":"117","author":"Sethi","year":"2000","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.rmed.2004.11.006_bib7","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1164\/ajrccm.153.5.8630597","article-title":"Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group","volume":"153","author":"Vestbo","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.rmed.2004.11.006_bib8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1164\/ajrccm\/140.3.737","article-title":"Intraepithelial T-lymphocyte subsets in the airways of normal subjects and of patients with chronic bronchitis","volume":"140","author":"Fournier","year":"1989","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"10.1016\/j.rmed.2004.11.006_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thorax.55.1.12","article-title":"Ongoing airway inflammation in patients with COPD who do not currently smoke","volume":"55","author":"Rutgers","year":"2000","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.rmed.2004.11.006_bib10","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1164\/ajrccm.156.5.9701081","article-title":"Inflammatory cells in the bronchial glands of smokers with chronic bronchitis","volume":"156","author":"Saetta","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.rmed.2004.11.006_bib11","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1164\/ajrccm.153.2.8564092","article-title":"Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma","volume":"153","author":"Keatings","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.rmed.2004.11.006_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/thorax.57.8.709","article-title":"Sputum chemotactic activity in chronic obstructive pulmonary disease","volume":"57","author":"Woolhouse","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2004.11.006_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/0470868678.ch5","article-title":"Mucus hypersecretion in chronic obstructive pulmonary disease","volume":"234","author":"Rogers","year":"2001","journal-title":"Novartis Found Symp"},{"issue":"5 Suppl 1","key":"10.1016\/j.rmed.2004.11.006_bib14","doi-asserted-by":"crossref","first-page":"251S","DOI":"10.1378\/chest.117.5_suppl_1.251S","article-title":"Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture","volume":"117","author":"Jeffery","year":"2000","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2004.11.006_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/thx.49.4.319","article-title":"Collagen content of alveolar wall tissue in emphysematous and non-emphysematous lungs","volume":"49","author":"Lang","year":"1994","journal-title":"Thorax"},{"issue":"Suppl","key":"10.1016\/j.rmed.2004.11.006_bib16","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1183\/09031936.03.00004603a","article-title":"Systemic inflammation in chronic obstructive pulmonary disease","volume":"46","author":"Oudijk","year":"2003","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.rmed.2004.11.006_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1183\/09031936.03.00405703","article-title":"Systemic effects of chronic obstructive pulmonary disease","volume":"21","author":"Agusti","year":"2003","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.rmed.2004.11.006_bib18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1164\/ajrccm.153.2.8564110","article-title":"Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients","volume":"153","author":"de Godoy","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.rmed.2004.11.006_bib19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/thorax.58.8.659","article-title":"Bronchodilator reversibility testing in chronic obstructive pulmonary disease","volume":"58","author":"Calverley","year":"2003","journal-title":"Thorax"},{"issue":"Suppl 2","key":"10.1016\/j.rmed.2004.11.006_bib20","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1378\/chest.117.2_suppl.23S","article-title":"Recommendations for the management of COPD","volume":"117","author":"Ferguson","year":"2000","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2004.11.006_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM200007273430407","article-title":"Chronic obstructive pulmonary disease","volume":"343","author":"Barnes","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2004.11.006_bib22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000063278","article-title":"Anticholinergics in the treatment of chronic obstructive pulmonary disease","volume":"69","author":"Beeh","year":"2002","journal-title":"Respiration"},{"issue":"8","key":"10.1016\/j.rmed.2004.11.006_bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJM198808253190806","article-title":"Ipratropium bromide","volume":"319","author":"Gross","year":"1988","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.rmed.2004.11.006_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1183\/09031936.02.00238702","article-title":"Improved health outcomes in patients with COPD during 1yr's treatment with tiotropium","volume":"19","author":"Vincken","year":"2002","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.rmed.2004.11.006_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"Casaburi","year":"2002","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.rmed.2004.11.006_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0306-3623(88)90021-3","article-title":"Beta-adrenoceptor function in asthmatic bronchial smooth muscle","volume":"19","author":"Lulich","year":"1988","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.rmed.2004.11.006_bib27","series-title":"Asthma and Rhinitis","first-page":"1278","article-title":"Mechanisms of action of the beta2-adrenoceptor agonists","author":"Johnson","year":"1995"},{"issue":"1","key":"10.1016\/j.rmed.2004.11.006_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1378\/chest.122.1.47","article-title":"A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol","volume":"122","author":"Donohue","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2004.11.006_bib29","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1378\/chest.125.5.1726","article-title":"The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD","volume":"125","author":"Hasani","year":"2004","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.rmed.2004.11.006_bib30","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1345\/aph.1C436","article-title":"Long-acting inhaled beta 2-agonists for stable COPD","volume":"37","author":"Dougherty","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.rmed.2004.11.006_bib31","first-page":"A93","article-title":"Salmeterol added to usual therapy gives a rapid improvement in lung function that is sustained at 6 and 12 months in patients with COPD","volume":"167","author":"Stockley","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.rmed.2004.11.006_bib32","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1378\/chest.115.4.957","article-title":"Efficacy of salmeterol xinafoate in the treatment of COPD","volume":"115","author":"Mahler","year":"1999","journal-title":"Chest"},{"issue":"9356","key":"10.1016\/j.rmed.2004.11.006_bib33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.rmed.2004.11.006_bib34","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1183\/09031936.02.00240902","article-title":"Formoterol in patients with chronic obstructive pulmonary disease","volume":"19","author":"Aalbers","year":"2002","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.rmed.2004.11.006_bib35","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1164\/ajrccm.164.5.2007006","article-title":"Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease","volume":"164","author":"Dahl","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.rmed.2004.11.006_bib36","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1378\/chest.121.4.1058","article-title":"Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD","volume":"121","author":"Rossi","year":"2002","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2004.11.006_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2004.11.006_bib38","first-page":"A636","article-title":"Salmeterol (S) speeds mucociliary transport (MCT) in healthy subjects","volume":"159","author":"Chambers","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.rmed.2004.11.006_bib39","first-page":"503","article-title":"The influence of a new beta agonist","volume":"9","author":"Melloni","year":"1992","journal-title":"Rev Mal Respir"},{"issue":"4","key":"10.1016\/j.rmed.2004.11.006_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0952-0600(92)90068-R","article-title":"The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro","volume":"5","author":"Devalia","year":"1992","journal-title":"Pulm Pharmacol"},{"issue":"1","key":"10.1016\/j.rmed.2004.11.006_bib41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1183\/09031936.98.11010086","article-title":"Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro","volume":"11","author":"Dowling","year":"1998","journal-title":"Eur Respir J"},{"issue":"4, Part 1","key":"10.1016\/j.rmed.2004.11.006_bib42","first-page":"580L","article-title":"Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells","volume":"272","author":"Bloemen","year":"1997","journal-title":"Am J Physiol"},{"issue":"4","key":"10.1016\/j.rmed.2004.11.006_bib43","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1164\/ajrccm.155.4.9105089","article-title":"Salmeterol reduces early and late-phase plasma leakage and leukocyte adhesion in rat airways","volume":"155","author":"Bolton","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.rmed.2004.11.006_bib44","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1152\/jappl.1994.77.1.397","article-title":"Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by beta 2-adrenergic agonist formoterol","volume":"77","author":"Bowden","year":"1994","journal-title":"J Appl Physiol"},{"issue":"suppl 45","key":"10.1016\/j.rmed.2004.11.006_bib45","first-page":"469S","article-title":"Inhaled salmeterol increases parasternal EMG activity","volume":"22","author":"Hawes","year":"2003","journal-title":"Eur Resp J"},{"issue":"4, Part 1","key":"10.1016\/j.rmed.2004.11.006_bib46","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1164\/ajrccm\/148.4_Pt_1.1030","article-title":"Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease","volume":"148","author":"Mulloy","year":"1993","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"10.1016\/j.rmed.2004.11.006_bib47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1378\/chest.101.1.160","article-title":"Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease","volume":"101","author":"Thomas","year":"1992","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.rmed.2004.11.006_bib48","first-page":"204","article-title":"The potential of PDE4 inhibitors in asthma or COPD","volume":"1","author":"Spina","year":"2000","journal-title":"Curr Opin Investig Drugs"},{"issue":"10","key":"10.1016\/j.rmed.2004.11.006_bib49","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1164\/rccm.2105106","article-title":"Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease","volume":"165","author":"Culpitt","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.rmed.2004.11.006_bib50","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1164\/rccm.200210-1142PP","article-title":"Theophylline","volume":"167","author":"Barnes","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"9410","key":"10.1016\/j.rmed.2004.11.006_bib51","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(04)15650-X","article-title":"Corticosteroid resistance in chronic obstructive pulmonary disease","volume":"363","author":"Barnes","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rmed.2004.11.006_bib52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000029466","article-title":"Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease","volume":"67","author":"Yildiz","year":"2000","journal-title":"Respiration"},{"issue":"6","key":"10.1016\/j.rmed.2004.11.006_bib53","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1378\/chest.117.6.1633","article-title":"Inhaled corticosteroids in stable COPD patients","volume":"117","author":"Balbi","year":"2000","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.rmed.2004.11.006_bib54","first-page":"A318","article-title":"Effect of fluticasone and salmeterol on human alveolar macrophage cytokine production in patients with chronic obstructive pulmonary disease (COPD)","volume":"167","author":"Seeto","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.rmed.2004.11.006_bib55","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1164\/rccm.2105025","article-title":"The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease","volume":"165","author":"Hattotuwa","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.rmed.2004.11.006_bib56","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/thorax.58.11.937","article-title":"Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease","volume":"58","author":"Sutherland","year":"2003","journal-title":"Thorax"},{"issue":"7245","key":"10.1016\/j.rmed.2004.11.006_bib57","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease","volume":"320","author":"Burge","year":"2000","journal-title":"Br Med J"},{"issue":"26","key":"10.1016\/j.rmed.2004.11.006_bib58","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1056\/NEJM200012283432601","article-title":"Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease","volume":"343","year":"2000","journal-title":"N Engl J Med"},{"issue":"9167","key":"10.1016\/j.rmed.2004.11.006_bib59","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(98)10019-3","article-title":"Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease","volume":"353","author":"Vestbo","year":"1999","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.rmed.2004.11.006_bib60","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1056\/NEJM199906243402503","article-title":"Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease","volume":"340","author":"Pauwels","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.rmed.2004.11.006_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/09031936.03.00063703","article-title":"Global strategy for the diagnosis, management and prevention of COPD","volume":"22","author":"Fabbri","year":"2003","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.rmed.2004.11.006_bib62","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.rmed.2004.11.006_bib63","first-page":"161","article-title":"An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease","volume":"93","author":"Jarad","year":"1999","journal-title":"ISOLDE Study Group. Respir Med"},{"issue":"6","key":"10.1016\/j.rmed.2004.11.006_bib64","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0091-6749(72)90131-5","article-title":"Complications of long-term steroid therapy for asthma","volume":"49","author":"Lieberman","year":"1972","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.rmed.2004.11.006_bib65","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM198308043090502","article-title":"Steroid-induced fractures and bone loss in patients with asthma","volume":"309","author":"Adinoff","year":"1983","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.rmed.2004.11.006_bib66","first-page":"43S","article-title":"Fracture incidence from clinical trials of fluticasone propionate alone or in combination with salmeterol in the treatment of chronic obstructive pulmonary disease","volume":"122","author":"Knobil","year":"2002","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.rmed.2004.11.006_bib67","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1183\/09031936.02.00276602","article-title":"Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler","volume":"19","author":"Johnell","year":"2002","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.rmed.2004.11.006_bib68","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.2001.16.3.581","article-title":"Use of inhaled corticosteroids and risk of fractures","volume":"16","author":"van Staa","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.rmed.2004.11.006_bib69","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1164\/ajrccm.164.4.2009033","article-title":"Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease","volume":"164","author":"Sin","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.rmed.2004.11.006_bib70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF03256640","article-title":"Inhaled corticosteroids with\/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients","volume":"2","author":"Soriano","year":"2003","journal-title":"Am J Respir Med"},{"key":"10.1016\/j.rmed.2004.11.006_bib71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1164\/rccm.200210-1231OC","article-title":"Effectiveness of inhaled corticosteroids in COPD","volume":"168","author":"Suissa","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.rmed.2004.11.006_bib72","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"Mahler","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2004.11.006_bib73","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate 250 mcg\/salmeterol 50 mcg combined in the Diskus inhaler for the treatment of chronic obstructive pulmonary disease","volume":"124","author":"Hanania","year":"2003","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.rmed.2004.11.006_bib74","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.rmed.2004.11.006_bib75","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1183\/09031936.02.00301302","article-title":"Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice","volume":"20","author":"Soriano","year":"2002","journal-title":"Eur Respir J"},{"issue":"Suppl 43","key":"10.1016\/j.rmed.2004.11.006_bib76","first-page":"38S","article-title":"The TORCH Study","volume":"22","author":"Hagan","year":"2003","journal-title":"Eur Resp J"},{"issue":"2","key":"10.1016\/j.rmed.2004.11.006_bib77","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00063198-200203000-00005","article-title":"New therapeutic drugs in the management of chronic obstructive pulmonary disease","volume":"8","author":"Rennard","year":"2002","journal-title":"Curr Opin Pulm Med"},{"issue":"6","key":"10.1016\/j.rmed.2004.11.006_bib78","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jaci.2004.03.018","article-title":"Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients","volume":"113","author":"Matthews","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2004.11.006_bib79","doi-asserted-by":"crossref","unstructured":"COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994;105(5):1411\u20139.","DOI":"10.1378\/chest.105.5.1411"},{"issue":"5","key":"10.1016\/j.rmed.2004.11.006_bib80","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1034\/j.1399-3003.2000.15e11.x","article-title":"Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium","volume":"15","author":"van Noord","year":"2000","journal-title":"Eur Respir J"},{"issue":"2 Part 1","key":"10.1016\/j.rmed.2004.11.006_bib81","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1164\/ajrccm.156.2.9611013","article-title":"Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group","volume":"156","author":"Repine","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"3 Part 1","key":"10.1016\/j.rmed.2004.11.006_bib82","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1164\/ajrccm.157.3.97-05009","article-title":"Exhaled nitric oxide in chronic obstructive pulmonary disease","volume":"157","author":"Maziak","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"3 Part 1","key":"10.1016\/j.rmed.2004.11.006_bib83","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1164\/ajrccm.154.3.8810624","article-title":"Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease","volume":"154","author":"Dekhuijzen","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.rmed.2004.11.006_bib84","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/thx.53.2.137","article-title":"New therapies for chronic obstructive pulmonary disease","volume":"53","author":"Barnes","year":"1998","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.rmed.2004.11.006_bib85","first-page":"405","article-title":"Oral acetylcysteine reduces exacerbation rate in chronic bronchitis","volume":"64","author":"Boman","year":"1983","journal-title":"Eur J Respir Dis"},{"issue":"4","key":"10.1016\/j.rmed.2004.11.006_bib86","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1183\/09031936.93.01040351","article-title":"Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis","volume":"1","author":"Rasmussen","year":"1988","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.rmed.2004.11.006_bib87","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/01902148609061497","article-title":"Inhibition by oral N-acetylcysteine of cigarette smoke-induced \u2018bronchitis\u2019 in the rat","volume":"10","author":"Rogers","year":"1986","journal-title":"Exp Lung Res"},{"issue":"2","key":"10.1016\/j.rmed.2004.11.006_bib88","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0041-008X(88)90091-9","article-title":"Glutathione metabolism and utilization of external thiols by cigarette smoke-challenged, isolated rat and rabbit lungs","volume":"96","author":"Joshi","year":"1988","journal-title":"Toxicol Appl Pharmacol"},{"issue":"Suppl A","key":"10.1016\/j.rmed.2004.11.006_bib89","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.1093\/jac\/43.suppl_1.97","article-title":"Infectious exacerbations of chronic bronchitis","volume":"43","author":"Sethi","year":"1999","journal-title":"J Antimicro Chem"},{"issue":"1","key":"10.1016\/j.rmed.2004.11.006_bib90","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0022-3565(24)29537-9","article-title":"Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro","volume":"297","author":"Hatzelmann","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.rmed.2004.11.006_bib91","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0022-3565(24)37847-4","article-title":"SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo","volume":"287","author":"Griswold","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.rmed.2004.11.006_bib92","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1164\/rccm.200212-1490OC","article-title":"Anti-inflammatory effects of the phosphodiesterase 4 inhibitor cilomilast (Ariflo) in COPD","volume":"168","author":"Gamble","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"9278","key":"10.1016\/j.rmed.2004.11.006_bib93","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0140-6736(01)05481-2","article-title":"Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease","volume":"358","author":"Compton","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rmed.2004.11.006_bib94","first-page":"48","article-title":"Development status of second generation PDE4 inhibitors for asthma and COPD","volume":"57","author":"Giembycz","year":"2002","journal-title":"Monaldi Arch Chest Dis"},{"issue":"6 Part 2","key":"10.1016\/j.rmed.2004.11.006_bib95","doi-asserted-by":"crossref","first-page":"109S","DOI":"10.1164\/ajrccm\/150.6_Pt_2.S109","article-title":"The role of proteinases in the pathogenesis of chronic bronchitis","volume":"150","author":"Stockley","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.rmed.2004.11.006_bib96","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1164\/ajrccm\/144.4.875","article-title":"Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase","volume":"144","author":"Williams","year":"1991","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"10.1016\/j.rmed.2004.11.006_bib97","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.192.6.789","article-title":"Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages","volume":"192","author":"Punturieri","year":"2000","journal-title":"J Exp Med"},{"issue":"2 Part 1","key":"10.1016\/j.rmed.2004.11.006_bib98","first-page":"305L","article-title":"Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats","volume":"270","author":"Massaro","year":"1996","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.rmed.2004.11.006_bib99","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1164\/ajrccm.165.5.2106123","article-title":"A pilot study of all-trans-retinoic acid for the treatment of human emphysema","volume":"165","author":"Mao","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.rmed.2004.11.006_bib100","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMra022361","article-title":"Adult stem cells for tissue repair\u2014a new therapeutic concept?","volume":"349","author":"Korbling","year":"2003","journal-title":"N Engl J Med"},{"issue":"2\u20133","key":"10.1016\/j.rmed.2004.11.006_bib101","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0162-3109(00)00206-X","article-title":"Inhibition of p38 MAP kinase as a therapeutic strategy","volume":"47","author":"Lee","year":"2000","journal-title":"Immunopharmacology"},{"issue":"5","key":"10.1016\/j.rmed.2004.11.006_bib102","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000050547","article-title":"Future advances in COPD therapy","volume":"68","author":"Barnes","year":"2001","journal-title":"Respiration"},{"issue":"2","key":"10.1016\/j.rmed.2004.11.006_bib103","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/thx.53.2.137","article-title":"New therapies for chronic obstructive pulmonary disease","volume":"53","author":"Barnes","year":"1998","journal-title":"Thorax"},{"issue":"Suppl","key":"10.1016\/j.rmed.2004.11.006_bib104","doi-asserted-by":"crossref","first-page":"50S","DOI":"10.1183\/09031936.01.00229701","article-title":"Cytokines in chronic obstructive pulmonary disease","volume":"34","author":"Chung","year":"2001","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.rmed.2004.11.006_bib105","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/thx.56.9.721","article-title":"Systemic anti-inflammatory mediators in COPD","volume":"56","author":"Dentener","year":"2001","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.rmed.2004.11.006_bib106","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1164\/rccm.2202023","article-title":"Local and systemic inflammation in patients with chronic obstructive pulmonary disease","volume":"166","author":"Vernooy","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.rmed.2004.11.006_bib107","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1164\/rccm.2108013","article-title":"Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease","volume":"166","author":"Agusti","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.rmed.2004.11.006_bib108","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1183\/09031936.98.12020380","article-title":"Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease","volume":"12","author":"Pesci","year":"1998","journal-title":"Eur Respir J"},{"issue":"17","key":"10.1016\/j.rmed.2004.11.006_bib109","doi-asserted-by":"crossref","first-page":"10095","DOI":"10.1074\/jbc.273.17.10095","article-title":"Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration","volume":"273","author":"White","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rmed.2004.11.006_bib110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000062157","article-title":"Interleukin 8 receptor (CXCR2) antagonists","volume":"31","author":"Sarau","year":"2001","journal-title":"New Drugs Asthma Allergy COPD"},{"key":"10.1016\/j.rmed.2004.11.006_bib111","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(03)12892-9","article-title":"Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors","volume":"361","author":"Anker","year":"2003","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.rmed.2004.11.006_bib112","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1164\/rccm.200404-543OC","article-title":"Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease","volume":"170","author":"Sin","year":"2004","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611104004330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611104004330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:13:22Z","timestamp":1760609602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611104004330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":112,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0954611104004330"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2004.11.006","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COPD, a multicomponent disease: implications for management","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2004.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}